Oramed Pharmaceuticals Inc. — Form 10-K Summary
Reporting period: Fiscal year ended August 31, 2012 (the filing is an annual report, not a standalone fourth-quarter report). Oramed is a development-stage pharmaceutical company focused on oral insulin and other oral peptide-drug delivery. It reported no product revenue.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense, net | $1.681 million | $1.159 million |
| General and administrative expense | $1.203 million | $1.276 million |
| Net loss | $3.344 million | $1.561 million |
| Basic and diluted loss per share | $0.05 | $0.02 |
| Cash used in operating activities | $2.302 million | $1.706 million |
- R&D expense increased about 45%, mainly reflecting preparation for a planned FDA-regulated Phase 2 study. Net loss more than doubled; the prior-year result included a $1.033 million gain on the sale of part of Entera.
- At August 31, 2012, cash and cash equivalents were $4.431 million, short-term deposits $454,000, and marketable securities $200,000. Current assets were $5.276 million and current liabilities $644,000; reported working capital was $4.439 million.
- Total liabilities were approximately $1.517 million, including $637,000 of warrant liabilities and a $228,000 provision for uncertain tax positions. The filing reports no conventional borrowings or off-balance-sheet arrangements.
- Shareholders’ equity was $3.778 million. Cash increased $2.917 million during the year, supported chiefly by equity financing; financing activities provided $3.489 million.
- Profit margins are not meaningful because the company had no revenue. The filing provides no operating-profit margin measure.
Business developments, outlook, and risks
- Lead candidate ORMD0801, an oral insulin capsule, was in non-FDA-approved Phase 2 studies. The company planned to submit an FDA Investigational New Drug application in calendar Q4 2012; it had not yet conducted an FDA-approved trial, and the filing does not confirm that the planned submission occurred.
- In September 2012, Oramed engaged Medpace for a U.S. Phase 2 trial expected to begin in Q1 2013 and finish in September 2013. The disclosed CRO consideration was approximately $3.5 million, payable against milestones.
- Management estimated $5.246 million of expenditures for the 12 months beginning September 1, 2012, including $4.198 million net R&D and $1.038 million general and administrative costs. Management expected available resources and subsequent financing to support planned activities for at least 12 months, while cautioning that further funding might be needed.
- Oramed reported approximately $1.490 million raised in equity financing from September through November 2012. The filing also describes August–November placements totaling approximately $5.050 million; these amounts cover different periods and should not be added together without checking the transaction details.
- Key risks include clinical failure or delay, regulatory approval uncertainty, need for additional capital, reliance on limited suppliers and potential commercial partners, patent protection, competition, and operations in Israel. Israeli government research grants may entail royalties and other restrictions if funded products are commercialized.
- The company recorded impairment charges of $184,000 on available-for-sale securities and $143,000 of expense from changes in warrant fair value. It also corrected a prior warrant-classification error in FY2012, concluding the prior-period error was immaterial and not restating prior statements.
- The financial statements received an unqualified audit opinion. Management nevertheless concluded that internal control over financial reporting was ineffective because of a material weakness in segregation of duties and limited accounting personnel.
- No material legal proceedings were reported. The company’s stock traded on the OTC Bulletin Board; it had applied for Nasdaq listing. Subsequent events included additional equity issuance and amendments to a major investor’s warrants.
Most important facts for investors to verify
- Whether the FDA IND was submitted and accepted, and whether the planned Phase 2 trial began, its cost, enrollment, and results.
- Cash runway after the disclosed post-year-end financing, actual spending versus the $5.246 million plan, and the timing and terms of future funding.
- Reconciliation of the differing post-year-end financing totals and the resulting fully diluted share count, including warrants and options.
- Progress in remediating the material weakness in financial-reporting controls and the status of any subsequent control assessment.
- Terms and potential dilution or value implications of the warrant amendments and the DNA Biomedical share transaction.